HIV treatment interruption and new drugs study
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests two investigational drugs (MGD014 and MGD020) in people with HIV who have had their virus well controlled on standard treatment for at least 2 years. Some participants will temporarily stop their HIV medicines to see how the new drugs work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have HIV that has been well controlled (virus level under 50 copies/mL) for at least 2 years on your current HIV medications.
- You must have a CD4 count (a measure of immune health) of 400 or higher.
- You must be willing to stay on your HIV meds during the study or stop them for up to 8 weeks under close monitoring.
- You cannot be pregnant or breastfeeding, and must use effective birth control if needed.
- You must not have certain health conditions, like active hepatitis C, untreated syphilis, or a history of blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests whether two drugs work together to reduce hidden HIV in your body while you're on stable HIV treatment. The goal is to understand how safe the combination is and whether it helps clear dormant HIV cells.
This study looks at a planned, supervised “treatment interruption” period for people with HIV who are very well controlled on HIV medicines. It mainly aims to understand what happens when therapy is paused and how to reduce the risk of passing HIV to others.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
This study looks at whether some people with HIV can keep the virus controlled even if they temporarily stop HIV medicines (an “analytic treatment interruption”). If you qualify, it may help researchers learn what it would take for an HIV cure.
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.